<p>香港，2026 年 5 月 4 日 -（ACN Newswire）-2026 年 5 月 4 日早上 6:18，随着最后生产工序的成功完成，中国旭阳集团在运城生产基地的 5 万吨/年己内酰胺转化为六亚甲基二胺（HMDA）工厂全面整合，实现了一次性成功投产并生产出合格产品。通过直接从己内酰胺生产 HMDA，中国旭阳打破了长期以来对己二腈技术的外国垄断（己二腈是 HMDA 的关键原料，是尼龙 66 的中间体，被视为尼龙产业链的 “咽喉”）。这一 “瓶颈” 技术的突破为中国旭阳在高端新材料领域的战略布局奠定了基础，逐步构建百万吨规模的 “尼龙 6 + 尼龙 66 + 特种尼龙” 产业集群，建立国家级尼龙新材料基地。</p>
<p>行业背景与当前发展</p>
<p>HMDA 是支持尼龙新材料产业升级的关键原料。其生产技术的创新与突破对中国化工行业的发展具有重要意义。目前，行业依赖于基于丁二烯的工艺生产己二腈，再转化为 HMDA。尽管这一路线已经成熟，但存在显著缺陷：一方面，由于丁二烯原料价格波动，生产成本依然较高；另一方面，工艺复杂，技术壁垒极高，关键专利长期被海外企业垄断。</p>
<p>在此背景下，中国旭阳集团开创了独立的研发路径，开发出一种新技术和工艺，直接从己内酰胺生产 HMDA。这一创新打破了行业垄断，克服了关键技术壁垒，为 HMDA 的生产开辟了新路径。</p>
<p>中国旭阳的研发历程与创新成就</p>
<p>作为全球最大的独立焦炭生产商和供应商，以及差异化煤化工运营的全球领导者，中国旭阳集团紧密对接国家战略需求，准确把握产业转型趋势。早在 2011 年，公司就预见到己内酰胺产业的潜力，扩大规模的同时建立研发团队，开展对己内酰胺及下游产业新工艺和技术的独立研究。</p>
<p>在十多年的时间里，中国旭阳的研发团队进行了超过一千次实验室规模的实验，稳步推进到中试规模建设和稳定运行，最终实现全面工业化。在从实验室到中试规模、工艺开发和工业化的过程中，团队攻克了百余个研究课题，获得了数十项拥有完全自主知识产权的核心专利，成功开发出直接从己内酰胺生产 HMDA 的创新工艺路线。</p>
<p>鉴于这一成就的颠覆性、开创性和战略价值，山东省已将中国旭阳集团的项目列为省级重点工程。</p>
<p>中国旭阳的核心产业优势与竞争力</p>
<p>HMDA 项目的投产凸显了中国旭阳在产业协同和研发创新方面的优势，显著提升了其在尼龙新材料领域的核心竞争力，巩固了其在化工行业的领导地位。</p>
<ol>
<li>稳定高效的产业协同</li>
</ol>
<p>HMDA 工厂的稳定运行和全面生产将与集团现有的 81 万吨/年己内酰胺产业链及运城工业园区的上游生产线（包括己二酸、环己酮和硝酸）形成协同。这种整合实现了资源互补、技术升级、产能扩张和效率最大化。</p>
<p>中国旭阳集团在芳烃产业链上具有坚实基础，从苯到己内酰胺再到 HMDA，进一步向下游高端产业（如聚合物颗粒、纤维纺织、织造、注塑、改性和聚氨酯）延伸。这加速了覆盖 “上游原材料 - 中游单体 - 下游产品” 的完整尼龙 6 + 尼龙 66 + 特种尼龙产业链的建设。</p>
<ol>
<li>持续的研发与创新能力</li>
</ol>
<p>与传统工艺相比，己内酰胺转化为 HMDA 技术具有明显优势：工艺流程简化、投资成本降低、安全性更高、原料转化率提高。</p>
<p>该工艺和催化剂均受中国旭阳的自主知识产权保护，突破了国内外在聚酰胺原料方面的技术壁垒，填补了中国的关键空白。</p>
<ol>
<li>持续的工艺优化与成本降低</li>
</ol>
<p>中国旭阳的己内酰胺转化为 HMDA 技术相比于丁二烯路线实现了显著降低的单位生产成本。未来研发与生产的整合将进一步降低运营成本。</p>
<p>作为全球第二大己内酰胺生产商，中国旭阳的规模优势、产业链整合和全面的配套基础设施使其 HMDA 产品具有高度的成本竞争力。</p>
<p>未来规划与发展战略</p>
<p>围绕己内酰胺产业链，中国旭阳集团已经开发并储备了多项技术和产品，包括 HMDA 和弹性尼龙。随着核心技术的持续稳定与升级，中国旭阳将扩大规模，为中国的尼龙 66 及相关产业注入新的动力。</p>
<p>展望未来，中国旭阳集团将继续致力于以创新驱动的发展和服务导向的增长，深化其垂直整合模式，战略性地培育高端化学品和新材料，并系统性地加强其新材料组合。公司致力于帮助中国进一步克服化学和新材料技术壁垒，构建现代化、自主可控的工业体系，实现尼龙 66 等关键材料的国产替代，为国家贡献中国旭阳的力量。</p>
<p>版权 © 2026 ACN Newswire。保留所有权利。</p>

中国旭阳集团

<p>中国旭阳集团已成功启动其新建的 5 万吨/年己二胺（HMDA）工厂，打破了对腈纶技术的外资垄断。这一创新使得可以直接从己内酰胺生产 HMDA，提升了中国的尼龙产业。该项目被山东省认定为重点工程，展示了旭阳的研发能力和产业协同，显著降低了生产成本并提高了效率。公司旨在扩大其尼龙相关产品的供应，并加强在高端化学品市场的地位</p>

<p>HONG KONG, May 4, 2026 - (ACN Newswire) - At 6:18 a.m. on May 4, 2026, with the successful completion of the final production process, China Risun Group's 50,000-ton/year caprolactam-to-hexamethylenediamine (HMDA) plant at the Yuncheng Production Base was fully integrated, achieving a one-time successful start-up and producing qualified products. By directly producing HMDA from caprolactam, China Risun has broken the long-standing foreign monopoly on adiponitrile technology (adiponitrile is the key raw material for HMDA, the intermediate for nylon 66, and is regarded as the 'throat' of the nylon industry chain). This breakthrough in 'chokepoint' technology lays the foundation for China Risun's strategic deployment in high-end new materials, gradually building a million-ton-scale 'nylon 6 + nylon 66 + specialty nylon' industrial cluster, and establishing a national-level nylon new materials base.</p>
<div class="lb-trans"><p>香港，2026 年 5 月 4 日 -（ACN Newswire）-2026 年 5 月 4 日早上 6:18，随着最后生产工序的成功完成，中国旭阳集团在运城生产基地的 5 万吨/年己内酰胺转化为六亚甲基二胺（HMDA）工厂全面整合，实现了一次性成功投产并生产出合格产品。通过直接从己内酰胺生产 HMDA，中国旭阳打破了长期以来对己二腈技术的外国垄断（己二腈是 HMDA 的关键原料，是尼龙 66 的中间体，被视为尼龙产业链的 “咽喉”）。这一 “瓶颈” 技术的突破为中国旭阳在高端新材料领域的战略布局奠定了基础，逐步构建百万吨规模的 “尼龙 6 + 尼龙 66 + 特种尼龙” 产业集群，建立国家级尼龙新材料基地。</p>
</div><p>Industry Background and Current Development</p>
<div class="lb-trans"><p>行业背景与当前发展</p>
</div><p>HMDA is a critical raw material supporting the upgrading of the nylon new materials industry. Innovation and breakthroughs in its production technology are of great significance to the development of China's chemical industry. Currently, the industry relies on the butadiene-based process to produce adiponitrile and then HMDA. Although mature, this route has notable shortcomings: on one hand, production costs remain high due to fluctuations in butadiene feedstock prices; on the other hand, the process is complex, with extremely high technical barriers, and key patents have long been monopolized by overseas enterprises.</p>
<div class="lb-trans"><p>HMDA 是支持尼龙新材料产业升级的关键原料。其生产技术的创新与突破对中国化工行业的发展具有重要意义。目前，行业依赖于基于丁二烯的工艺生产己二腈，再转化为 HMDA。尽管这一路线已经成熟，但存在显著缺陷：一方面，由于丁二烯原料价格波动，生产成本依然较高；另一方面，工艺复杂，技术壁垒极高，关键专利长期被海外企业垄断。</p>
</div><p>Against this backdrop, China Risun Group pioneered an independent R&amp;D path, developing a new technology and process to directly produce HMDA from caprolactam. This innovation breaks industry monopolies, overcomes critical technical barriers, and opens up a new route for HMDA production.</p>
<div class="lb-trans"><p>在此背景下，中国旭阳集团开创了独立的研发路径，开发出一种新技术和工艺，直接从己内酰胺生产 HMDA。这一创新打破了行业垄断，克服了关键技术壁垒，为 HMDA 的生产开辟了新路径。</p>
</div><p>China Risun's R&amp;D Journey and Innovation Achievements</p>
<div class="lb-trans"><p>中国旭阳的研发历程与创新成就</p>
</div><p>As the world's largest independent coke producer and supplier, and a global leader in differentiated coal chemical operations, China Risun Group has closely aligned with national strategic needs and accurately grasped industrial transformation trends. As early as 2011, the company foresaw the potential of the caprolactam industry, expanding its scale while establishing R&amp;D teams to carry out independent research on new processes and technologies for caprolactam and downstream industries.</p>
<div class="lb-trans"><p>作为全球最大的独立焦炭生产商和供应商，以及差异化煤化工运营的全球领导者，中国旭阳集团紧密对接国家战略需求，准确把握产业转型趋势。早在 2011 年，公司就预见到己内酰胺产业的潜力，扩大规模的同时建立研发团队，开展对己内酰胺及下游产业新工艺和技术的独立研究。</p>
</div><p>Over more than a decade, China Risun's R&amp;D team conducted over a thousand laboratory-scale experiments, steadily advancing to pilot-scale construction and stable operation, and ultimately achieving full industrial implementation. Throughout the journey from lab-scale to pilot-scale, process development, and industrialization, the team tackled over a hundred research topics, secured dozens of core patents with fully independent intellectual property rights, and successfully developed the innovative process route of directly producing HMDA from caprolactam.</p>
<div class="lb-trans"><p>在十多年的时间里，中国旭阳的研发团队进行了超过一千次实验室规模的实验，稳步推进到中试规模建设和稳定运行，最终实现全面工业化。在从实验室到中试规模、工艺开发和工业化的过程中，团队攻克了百余个研究课题，获得了数十项拥有完全自主知识产权的核心专利，成功开发出直接从己内酰胺生产 HMDA 的创新工艺路线。</p>
</div><p>Given the disruptive, pioneering, and strategic value of this achievement, Shandong Province has designated China Risun Group's project as a provincial key engineering initiative.</p>
<div class="lb-trans"><p>鉴于这一成就的颠覆性、开创性和战略价值，山东省已将中国旭阳集团的项目列为省级重点工程。</p>
</div><p>China Risun's Core Industrial Advantages and Competitiveness</p>
<div class="lb-trans"><p>中国旭阳的核心产业优势与竞争力</p>
</div><p>The commissioning of the HMDA project highlights China Risun's strengths in industrial synergy and R&amp;D innovation, significantly enhancing its core competitiveness in nylon new materials and consolidating its leadership position in the chemical industry.</p>
<div class="lb-trans"><p>HMDA 项目的投产凸显了中国旭阳在产业协同和研发创新方面的优势，显著提升了其在尼龙新材料领域的核心竞争力，巩固了其在化工行业的领导地位。</p>
</div><p>1. Stable and Efficient Industrial Synergy</p>
<div class="lb-trans"><ol>
<li>稳定高效的产业协同</li>
</ol>
</div><p>The stable operation and full-scale production of the HMDA plant will synergize with the Group's existing 810,000-ton/year caprolactam industry chain and upstream production lines at Yuncheng Industrial Park, including adipic acid, cyclohexanone, and nitric acid. This integration enables resource complementarity, technological upgrading, capacity expansion, and maximized efficiency.</p>
<div class="lb-trans"><p>HMDA 工厂的稳定运行和全面生产将与集团现有的 81 万吨/年己内酰胺产业链及运城工业园区的上游生产线（包括己二酸、环己酮和硝酸）形成协同。这种整合实现了资源互补、技术升级、产能扩张和效率最大化。</p>
</div><p>China Risun Group has a strong foundation in the aromatics industry chain, extending from benzene to caprolactam to HMDA, and further downstream into high-end industries such as polymer chips, fiber spinning, weaving, injection molding, modification, and polyurethane. This accelerates the construction of a full nylon 6 + nylon 66 + specialty nylon industry chain covering 'upstream raw materials - midstream monomers - downstream products.'</p>
<div class="lb-trans"><p>中国旭阳集团在芳烃产业链上具有坚实基础，从苯到己内酰胺再到 HMDA，进一步向下游高端产业（如聚合物颗粒、纤维纺织、织造、注塑、改性和聚氨酯）延伸。这加速了覆盖 “上游原材料 - 中游单体 - 下游产品” 的完整尼龙 6 + 尼龙 66 + 特种尼龙产业链的建设。</p>
</div><p>2. Continuous R&amp;D and Innovation Capacity</p>
<div class="lb-trans"><ol>
<li>持续的研发与创新能力</li>
</ol>
</div><p>Compared with traditional processes, the caprolactam-to-HMDA technology offers clear advantages: simplified process flow, lower investment costs, higher safety, and improved raw material conversion rates.</p>
<div class="lb-trans"><p>与传统工艺相比，己内酰胺转化为 HMDA 技术具有明显优势：工艺流程简化、投资成本降低、安全性更高、原料转化率提高。</p>
</div><p>Both the process and catalyst are protected by China Risun's independent intellectual property rights, breaking through domestic and international technical barriers in polyamide raw materials and filling a critical gap in China.</p>
<div class="lb-trans"><p>该工艺和催化剂均受中国旭阳的自主知识产权保护，突破了国内外在聚酰胺原料方面的技术壁垒，填补了中国的关键空白。</p>
</div><p>3. Ongoing Process Optimization and Cost Reduction</p>
<div class="lb-trans"><ol>
<li>持续的工艺优化与成本降低</li>
</ol>
</div><p>China Risun's caprolactam-to-HMDA technology achieves significantly lower unit production costs compared with the butadiene route. Future integration of R&amp;D and production will further reduce operating costs.</p>
<div class="lb-trans"><p>中国旭阳的己内酰胺转化为 HMDA 技术相比于丁二烯路线实现了显著降低的单位生产成本。未来研发与生产的整合将进一步降低运营成本。</p>
</div><p>As the world's second-largest caprolactam producer, China Risun's scale advantages, industry chain integration, and comprehensive supporting infrastructure make its HMDA products highly cost-competitive.</p>
<div class="lb-trans"><p>作为全球第二大己内酰胺生产商，中国旭阳的规模优势、产业链整合和全面的配套基础设施使其 HMDA 产品具有高度的成本竞争力。</p>
</div><p>Future Planning and Development Strategy</p>
<div class="lb-trans"><p>未来规划与发展战略</p>
</div><p>Around the caprolactam industry chain, China Risun Group has already developed and reserved multiple technologies and products, including HMDA and elastic nylon. With the continuous stabilization and upgrading of its core technologies, China Risun will expand its scale and inject new momentum into China's nylon 66 and related industries.</p>
<div class="lb-trans"><p>围绕己内酰胺产业链，中国旭阳集团已经开发并储备了多项技术和产品，包括 HMDA 和弹性尼龙。随着核心技术的持续稳定与升级，中国旭阳将扩大规模，为中国的尼龙 66 及相关产业注入新的动力。</p>
</div><p>Looking ahead, China Risun Group will remain committed to innovation-driven development and service-oriented growth, deepening its vertically integrated model, strategically cultivating high-end chemicals and new materials, and systematically strengthening its new materials portfolio. The company is dedicated to helping China further overcome chemical and new materials technology barriers, building a modernized, autonomous, and controllable industrial system, and achieving domestic substitution of key materials such as nylon 66-contributing China Risun's strength to the nation.</p>
<div class="lb-trans"><p>展望未来，中国旭阳集团将继续致力于以创新驱动的发展和服务导向的增长，深化其垂直整合模式，战略性地培育高端化学品和新材料，并系统性地加强其新材料组合。公司致力于帮助中国进一步克服化学和新材料技术壁垒，构建现代化、自主可控的工业体系，实现尼龙 66 等关键材料的国产替代，为国家贡献中国旭阳的力量。</p>
</div><p>Copyright 2026 ACN Newswire . All rights reserved.</p>
<div class="lb-trans"><p>版权 © 2026 ACN Newswire。保留所有权利。</p>
</div>

突破 “卡脖子” 技术：中国旭阳集团的己二胺工厂已开始投产